In HER2-amplified NSCLC, phase II trials have shown no clinical benefit of trastuzumab monotherapy, trastuzumab with chemotherapy, trastuzumab emtansine, or pertuzumab [114,115,116,117]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.